Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ ZenaTech Expands Drone as a Service (DaaS) for Government and Defense, Signing an Offer to Acquire a... (GlobeNewswire EN) +++ ZENATECH Aktie +7,78%

PLUS THERAPEUTICS Aktie

>Performance
1 Woche: 0%
1 Monat: 0%
3 Monate: 0%
6 Monate: +10,6%
1 Jahr: -36,6%
laufendes Jahr: +1,2%
>PLUS THERAPEUTICS Aktie
Name:  PLUS THERAPEUTICS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US72941H5090 / A3EEZB
Symbol/ Ticker:  XMP0 (Frankfurt) / PSTV (NASDAQ)
Kürzel:  FRA:XMP0, ETR:XMP0, XMP0:GR, NASDAQ:PSTV
Index:  -
Webseite:  https://plustherapeutics...
Marktkapitalisierung:  8.86 Mio. EUR
Umsatz:  4.51 Mio. EUR
EBITDA:  -12.31 Mio. EUR
Gewinn je Aktie:  -1.792 EUR
Schulden:  0.03 Mio. EUR
Liquide Mittel:  8.55 Mio. EUR
Umsatz-/ Gewinnwachstum:  -36.9% / -
KGV/ KGV lG:  0.71 / -
KUV/ KBV/ PEG:  23.3 / 3.49 / -
Gewinnm./ Eigenkapitalr.:  -222.84% / -
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  PLUS THERAPEUTICS, PLUS THERAPEUTIC
Letzte Datenerhebung:  24.06.25
>Eigentümer
Aktien: 32.72 Mio. St.
f.h. Aktien: 14.01 Mio. St.
Insider Eigner: 9.29%
Instit. Eigner: 3.9%
>Peer Group

 
24.06.25 - 13:33
 Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing (GlobeNewswire EN)
 
Comprehensive restructuring eliminates the potential issuance of up to 1.5 billion shares of common stock Plus Therapeutics files a request to withdraw the related resale registration statement with the SEC...
18.06.25 - 13:36
 Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
02.06.25 - 06:33
 Plus Therapeutics GAAP EPS of -$1.19 misses by $0.97, revenue of $1.06M misses by $0.08M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
31.05.25 - 01:00
 Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
 
Plus (PSTV) delivered earnings and revenue surprises of -229.41% and 42.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?...
30.05.25 - 22:18
 Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights (GlobeNewswire EN)
 
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights...
23.05.25 - 22:39
 Plus Therapeutics recives Nasdaq delinquency notice (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
23.05.25 - 22:18
 Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q (GlobeNewswire EN)
 
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q...
14.05.25 - 17:30
 Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
 
Plus (PSTV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
23.04.25 - 14:03
 Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors (GlobeNewswire EN)
 
HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the appointment of Kyle Guse, J.D., M.B.A. to the Company's Board of Directors where he will serve as chair of the Audit Committee and on the Compensation Committee....
15.04.25 - 14:24
 Plus Therapeutics: ReSPECT-LM Data Shows Potential Utility Of REYOBIQ (AFX)
 
WASHINGTON (dpa-AFX) - Plus Therapeutics (PSTV) reported the online availability of new data on its lead compound REYOBIQ. The additional data from the Phase 1 ReSPECT-LM dose escalation trial dem......
15.04.25 - 13:33
 Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (GlobeNewswire EN)
 
New abstract published ahead of the Nuclear Medicine and Neurooncology Conference shows promise for REYOBIQ New abstract published ahead of the Nuclear Medicine and Neurooncology Conference shows promise for REYOBIQ...
04.04.25 - 22:45
 Plus Therapeutics files to sell 1.57B shares of common stock for holders (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
28.03.25 - 00:48
 Plus Therapeutics outlines REYOBIQ expansion plans and CNSide launch timeline (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
28.03.25 - 00:00
 Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
 
Plus (PSTV) delivered earnings and revenue surprises of -31.37% and 6.49%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?...
26.03.25 - 22:42
 Plus Therapeutics Q4 2024 Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
21.03.25 - 18:45
 PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug (Zacks)
 
The FDA conditionally accepts Plus Therapeutics' new proprietary name, Reyobiq, for its lead therapeutic candidate. Stock shoots up....
20.03.25 - 13:24
 Why Plus Therapeutics Is Rising In Pre-market? (AFX)
 
WASHINGTON (dpa-AFX) - Plus Therapeutics (PSTV) announced the FDA has conditionally accepted the company's new proprietary name, REYOBIQ, for its lead therapeutic candidate. The company noted that......
20.03.25 - 12:33
 Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate (GlobeNewswire EN)
 
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate...
19.03.25 - 12:33
 Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025 (GlobeNewswire EN)
 
Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Was man zu lang bedenkt, das wird bedenklich. - Sprichwort
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!